Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05629546 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | suspended | Phase 1 | 33 | Washington University School of MedicineOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | suspended | Phase 1 | 18 | University of FloridaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03384836 | Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | suspended | Phase 1 / Phase 2 | 47 | Roswell Park Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors | suspended | Phase 1 | 100 | University of California, DavisOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | suspended | Phase 1 | 30 | DNAtrix, Inc.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03932253 | MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) | suspended | Phase 1 | 79 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT01841463 | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation | suspended | Phase 1 | 100 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
| NCT00160992 | Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients | suspended | Phase 1 | 6 | University of Lausanne HospitalsOTHER | 1 | Sep 12, 2005 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials